摘要
背景:与其他疾病相比,心血管疾病(CVD)的全球死亡率最高。 与CVD相关的主要危险因素是高血压。 目前的抗高血压(AHT)疗法的主要类型包括血管紧张素转换酶抑制剂(ACEI),血管紧张素受体阻断剂(ARB)和钙通道阻滞剂(CCBs)。 所有这些抗高血压治疗药物具有低口服生物利用度,并且可以诱导上呼吸道抽取,血管性水肿,反射性心动过速和口服后极度的降血压作用,这可引起心脏病患者的致死作用。 目的:通过使用抗高血压药物进行控制和靶向释放可以提供更好的解决方案,克服上述副作用。 结果:开发基于生物聚合物的纳米载体系统的科学进化为安全和/或可食用的纳米药物递送系统开辟了新的视野。在本文中,我们详细回顾了AHT药物的各种机制,与目前的治疗策略相关的主要吸引力,以及AHT纳米药物与常规药物相比的优势。此外,最近有关具有不同AHT药物的生物基纳米/微载体系统的报告已经被分析了其主要特征。壳聚糖作为AHT药物的潜在携带者,由于其独特的性质,包括粘膜粘附性,渗透性以及其生物相容性和生物可降解性,已作深入回顾。 结论:基于壳聚糖的新型AHT纳米凝胶可以通过其在GIT下部的持续释放来改善口服生物利用度,降低疏水性并增加AHT药物的血浆半衰期。
关键词: 纳米载体系统,高血压,抗高血压治疗,壳聚糖纳米颗粒,ACE抑制剂,药物递送。
图形摘要
Current Drug Targets
Title:Prospectives of Antihypertensive Nano-ceuticals as Alternative Therapeutics
Volume: 18 Issue: 11
关键词: 纳米载体系统,高血压,抗高血压治疗,壳聚糖纳米颗粒,ACE抑制剂,药物递送。
摘要: Background: Global death rate due to cardiovascular diseases (CVDs) is highest as compared to other ailments. Principal risk factor associated with CVDs is hypertension. Major classes of current antihypertensive (AHT) therapies include angiotensin converting enzyme inhibitors (ACEI), angiotensin receptor blockers (ARBs) and calcium channel blockers (CCBs). All these antihypertensive therapeutic drugs have low oral bioavailability and can induce upper respiratory tract abstraction, angioedema, reflex tachycardia and extreme hypotensive effect after oral administration which can cause lethal effects in patients with heart diseases.
Objective: Controlled and targeted release by using antihypertensive nano-medicines can provide better solution to overcome above-mentioned side effects. Results: Scientific evolution towards the development of biopolymer based nano-carrier systems has unlocked new horizons for safe and/or edible nano drug delivery systems. In this article, we have reviewed in detail various mechanisms of AHT drugs, major draw backs associated with current therapeutic strategies, and the advantages of AHT nano-medicines over conventional drugs. Furthermore, recent reports of bio-based nano/micro -carrier systems with different AHT drugs have been analyzed with their key features. In depth review has been presented for chitosan as a potential carrier of AHT drugs due to its distinctive properties comprising muco-adhesive attribute, permeation enhancement as well as its biocompatible and biodegradable nature. Conclusion: Chitosan based novel AHT nano-ceuticals can improve oral bioavailability, reduce hydrophobicity and increase the plasma half-life of AHT drugs by their sustained release in lower part of the GIT.Export Options
About this article
Cite this article as:
Prospectives of Antihypertensive Nano-ceuticals as Alternative Therapeutics, Current Drug Targets 2017; 18 (11) . https://dx.doi.org/10.2174/1389450117666160711163119
DOI https://dx.doi.org/10.2174/1389450117666160711163119 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Obstructive Sleep Apnoea Syndrome and Diabetes. Fortuitous Association or Interaction?
Current Diabetes Reviews PUFA Supplements and Type 2 Diabetes in the Elderly
Current Pharmaceutical Design Secondary Hypertension: The Ways of Management
Current Vascular Pharmacology Harnessing Polypharmacology with Computer-Aided Drug Design and Systems Biology
Current Pharmaceutical Design The Role of Angiogenesis in Coronary Artery Disease: A Double-Edged Sword: Intraplaque Angiogenesis in Physiopathology and Therapeutic Angiogenesis for Treatment
Current Pharmaceutical Design Oral Antidiabetic Agents: Anti-Atherosclerotic Properties Beyond Glucose Lowering?
Current Pharmaceutical Design Epoxide Hydrolases and their Application in Organic Synthesis
Current Organic Chemistry Stem Cell Therapies
Recent Patents on Regenerative Medicine Vulnerable Plaque Versus Vulnerable Patient: Emerging Blood Biomarkers for Risk Stratification
Endocrine, Metabolic & Immune Disorders - Drug Targets Antioxidant Therapy and Drugs Interfering with Lipid Metabolism: Could They Be Effective in NAFLD Patients?
Current Pharmaceutical Design Combination Therapy of Statins with Ezetimibe
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Patent Selections
Recent Patents on Cardiovascular Drug Discovery miRNAs in Cancer Prevention and Treatment and as Molecular Targets for Natural Product Anticancer Agents
Current Cancer Drug Targets Atrial Fibrillation in Acute St-Elevation Myocardial Infarction: Clinical and Prognostic Features
Current Cardiology Reviews Spontaneous Pneumothorax
Current Respiratory Medicine Reviews Cardioprotective Properties of HDL: Structural and Functional Considerations
Current Medicinal Chemistry Meet Our Editorial Board Member
Current Cardiology Reviews Overview of Hyperuricaemia and Gout
Current Pharmaceutical Design Resistin: An Inflammatory Cytokine. Role in Cardiovascular Diseases, Diabetes and the Metabolic Syndrome
Current Pharmaceutical Design Natural and Synthetic Naphthoquinones Active Against Trypanosoma Cruzi: An Initial Step Towards New Drugs for Chagas Disease
Current Medicinal Chemistry